Jeff Sharman, MD

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).